Basic Search  |  Summaries  |  Advanced Search

Violation Tracker Individual Record

Company: Johnson & Johnson
Current Parent CompanyJohnson & Johnson
Parent at the Time of the Penalty Announcement subscribe to see this data field
Penalty: $158,000,000
Year: 2012
Date: January 19, 2012
Offense Group: healthcare-related offenses
Primary Offense: off-label or unapproved promotion of medical products
Secondary Offense: False Claims Act and related
Mega-ScandalImproper Drug Marketing
Violation Description: Johnson & Johnson and its subsidiary Janssen agreed to pay $158 million to settle allegations that it improperly urged physicians to prescribe the drug Risperdal to children and the elderly for schizophrenia and dementia, despite the fact that the drug had not been approved by the U.S. Food and Drug Administration for these uses at the time.
Level of Government: state
Action Type: agency action
Agency: Texas Attorney General
Civil or Criminal Case: civil
Facility State: Texas
HQ Country of Current Parent: USA
HQ State of Current Parent: New Jersey
Ownership Structure of Current Parent: publicly traded
Major Industry of Current Parent: pharmaceuticals
Specific Industry of Current Parent: pharmaceuticals
Source of Data: Texas Attorney General Secures $158 Million Agreement with Drug Maker Over Medicaid Fraud Allegations, Targeted News Service, January 19, 2012 (via Nexis).
Source Notes: If an online information source is not working, check the Violation Tracker Data Sources page for an updated link.
Current parent company note: Parent-subsidiary relationship is current as of the most recent revision listed in the Update Log.